LEGN
NASDAQ
US
Legend Biotech Corporation - American Depositary Shares
$19.14
▲ +$0.09
(+0.47%)
Vol 1.2M
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.0B
ROE
-23.4%
Margin
-26.4%
D/E
40.57
Beta
0.08
52W
$21–$45
Wall Street Consensus
24 analysts · Apr 20267
Strong Buy
14
Buy
3
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
DNLI
Denali Therapeutics Inc
$2.6B
DYN
Dyne Therapeutics Inc
$3.2B
TNGX
Tango Therapeutics Inc
$1.2B
TWST
Twist Bioscience Corp
$1.9B
CPRX
Catalyst Pharmaceuticals Inc
P/E 13.2
$2.9B
Earnings
Beat rate: 20.0%
Next Report
May 11, 2026
EPS Estimate: $-0.03
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.03 | — | — |
| Dec 2025 | $-0.11 | $-0.16 | $-0.05 |
| Sep 2025 | $-0.09 | $-0.22 | $-0.13 |
| Jun 2025 | $-0.15 | $-0.68 | $-0.53 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $186.5M | $195.1M | $255.1M | $272.3M | $306.4M |
| Net Income | — | $26.3M | -$100.9M | -$125.4M | -$39.7M | -$30.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -30.9% | -30.9% | -30.9% | -30.9% | -23.4% | -23.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -49.2% | -40.8% | -40.8% | -40.8% | -26.4% | -26.4% |
| Gross Margin | 61.6% | 62.5% | 62.5% | 62.5% | 60.5% | 60.5% |
| D/E Ratio | 37.46 | 37.46 | 37.46 | 37.46 | 40.57 | 40.57 |
| Current Ratio | 4.71 | 4.71 | 4.71 | 4.71 | 2.86 | 2.86 |
Key Ratios
ROA (TTM)
-14.4%
P/S (TTM)
4.42
P/B
5.7
EPS (TTM)
$-0.65
Rev Growth 3Y
+108.9%
52W High
$45.30
52W Low
$21.19
$21.19
52-Week Range
$45.30
Financial Health
Free Cash Flow
-$24.6M
Net Debt
-$488.2M
Cash
$901.9M
Total Debt
$413.7M
As of Dec 31, 2025
How does LEGN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
LEGN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
4.4
▼
66%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
5.7
▲
133%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
LEGN profitability vs Biotechnology peers
ROE
-23.4%
▲
65%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-26.4%
▲
91%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
60.6%
▼
23%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-14.4%
▲
69%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
LEGN financial health vs Biotechnology peers
D/E ratio
40.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.9
▼
35%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.1
▼
92%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
LEGN fundamentals radar
LEGN
Peer median
Industry
LEGN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
LEGN vs peers: key metrics
Top Holders
Top 5: 26.47%FMR, LLC
13.12%
$407.7M
Suvretta Capital Management…
3.57%
$111.0M
Westfield Capital Managemen…
3.33%
$103.6M
HHLR Advisors, LTD
3.24%
$100.5M
Deerfield Management Compan…
3.21%
$99.7M
As of Dec 31, 2025
Latest News
No related news yet